Ketogenic Diet Gains Attention as a Therapy for Psychiatric Conditions

Why psychiatry is taking keto seriously

Keto is getting a real hearing in mental health because the story has moved past lifestyle buzz and into brain metabolism. The emerging argument is not that fat fixes everything, but that some serious psychiatric illnesses may respond when the brain gets a different fuel supply, especially when inflammation, mitochondrial stress, and glucose handling are part of the picture.

That is a very different claim from the usual internet version of keto. The researchers driving this work are talking about remission, symptom improvement, and a new treatment paradigm, not a miracle diet that cures schizophrenia overnight. For anyone who has spent time in the keto world, the important shift is this: the conversation is now about clinical psychiatry, not just macros.

The medical roots go back a century

This is not a trendy idea invented for social media. The ketogenic diet was developed more than a century ago for epilepsy, and Johns Hopkins’ epilepsy history places its medical use in the 1920s. An epilepsy history paper also points to Russell Wilder’s 1921 publications as pivotal in establishing ketonemia as a legitimate medical tool for seizure control.

That history matters because it shows keto entered medicine through neurology, not wellness culture. In other words, the diet already has a long track record of being used as a therapeutic intervention under supervision. Psychiatry is the new frontier, but the underlying idea that ketones can change brain function is not new at all.

What the current evidence actually looks like

The strongest modern signal comes from small pilots and real-world clinical reports, not from huge definitive trials. Stanford followed 21 adults with schizophrenia or bipolar disorder for four months, all of them already on antipsychotic medications and also dealing with metabolic problems such as weight gain, insulin resistance, hypertriglyceridemia, dyslipidemia, or impaired glucose tolerance. The diet was built in a classic therapeutic keto range, roughly 10% carbohydrate, 30% protein, and 60% fat.

That Stanford pilot reported improvements in both metabolic health and psychiatric symptoms. The point is not that everyone got better, but that the signal was strong enough to justify a second look. The completed trial is now being followed by a larger randomized study designed to test schizophrenia, bipolar disorder, and major depressive disorder more rigorously.

The field also has encouraging but still limited metabolic-brain data. In a 2025 bipolar disorder pilot, 27 people were recruited, 26 started, and 20 finished. Among completers, anterior cingulate glutamate plus glutamine fell by 11.6%, and posterior cingulate glutamate plus glutamine fell by 13.6%. That is the kind of result metabolic psychiatry researchers get excited about, because it suggests the intervention may be changing brain chemistry, not just body weight.

The conditions with the strongest support so far

If you want the blunt answer, schizophrenia and bipolar disorder have the clearest early support right now, especially in patients who also have metabolic dysfunction. That is where the Stanford pilot sits, and that is also where the Toulouse inpatient analysis has been widely cited. In that retrospective study of 31 inpatients with major depression, bipolar disorder, or schizophrenia, 28 stayed on the diet for more than two weeks, all 28 improved, 43% achieved clinical remission, and 64% left the hospital on less psychiatric medication.

That said, the evidence is still uneven across diagnoses. Major depressive disorder is getting more attention, but the dataset is thinner and more mixed. A 2025 JAMA Psychiatry meta-analysis of 50 studies found ketogenic diets were linked to small-to-moderate improvements in depressive symptoms in randomized trials, with larger effects in quasi-experimental studies. A 2026 systematic review found only eight eligible studies on ketogenic and low-carbohydrate diets for depression and anxiety published from 2019 to 2024.

Anorexia has also been mentioned in the broader discussion, but the evidence there is much less developed than in schizophrenia and bipolar disorder. Right now, the safest way to read the field is to say that mood disorders and psychotic disorders are being studied seriously, but the most concrete clinical momentum sits around serious mental illness with metabolic abnormalities.

Why the mechanism is getting attention

The reason keto is being discussed as more than a calorie strategy is that it touches several systems psychiatry has not historically centered. A 2024 review described ketogenic diets as a potential transdiagnostic treatment, pointing to shared mechanisms such as mitochondrial dysfunction, inflammation, oxidative stress, glucose hypometabolism, and glutamate/GABA imbalance. That is a mouthful, but it adds up to one big idea: some brains may struggle with energy regulation, and ketones may help provide a steadier fuel source.

Stanford’s Shebani Sethi and other researchers have argued that this may explain why some patients improve even while staying on antipsychotic medication. The trial protocol itself links these illnesses to cerebral glucose hypometabolism, oxidative stress, mitochondrial dysfunction, neurotransmitter dysfunction, reduced glucose uptake, and downstream synaptic effects. In plain English, the brain may not just be over- or under-signaling chemicals, it may also be struggling to make and use energy efficiently.

Why supervision is non-negotiable

This is not a DIY protocol you should borrow from a bodybuilding forum. The Stanford pilot only included adults with schizophrenia or bipolar disorder who had clear metabolic issues, and they were monitored while remaining on prescribed psychiatric medications. That matters because abrupt medication changes, electrolyte shifts, sleep disruption, and poor adherence can all complicate psychiatric care fast.

If someone is considering this territory, the medical setup usually needs to cover several basics:

• Psychiatric oversight, so medication changes are deliberate and symptom tracking is tight.
• Medical monitoring, especially for glucose, lipids, weight, blood pressure, and other metabolic markers.
• A realistic keto formulation, because therapeutic keto in these studies is not the same as casual low-carb eating.
• A plan for side effects and adherence, since the diet has to be sustained long enough to matter.

The point is not to scare people off. The point is to treat this as a clinical intervention, not a weekend experiment with extra bacon.

Where the field is headed next

The momentum is no longer confined to academic curiosity. ClinicalTrials.gov lists the Stanford study as completed, and the follow-on randomized trial is designed to test schizophrenia, bipolar disorder, and major depressive disorder in a larger, more definitive way. An editorial in the field has even called it the world’s first randomized controlled trial of ketogenic diet therapy in serious mental illness, which tells you how quickly the conversation is moving.

Institutionally, the area is gaining a foothold too. McLean Hospital launched a Metabolic and Mental Health Program with a $3 million donation, and Christopher Palmer is central to that effort as founder and director. McLean’s own framing is telling: it points to patients with psychotic disorders who have had fewer symptoms or needed fewer medications on a strict ketogenic diet. That is not a cure claim. It is a sign that psychiatry is starting to treat metabolism as a serious variable.

For keto fans, the honest takeaway is simple. This is not proof that a ketogenic diet should replace standard psychiatric treatment, and it is not a license to self-treat severe mental illness. It is evidence that keto may have a real, medically supervised role in a narrow but important slice of psychiatry, especially when serious mental illness and metabolic dysfunction overlap.